Article
The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
The American journal of pathology - 1 Jun 2013
Nakles Rebecca E, Kallakury Bhaskar V S, Furth Priscilla A
Abstract excerpt
Peroxisome proliferator-activated receptor gamma (PPARγ) agonists have anticancer activity and influence cell differentiation. We examined the impact of the selective PPARγ agonist efatutazone on mammary cancer pathogenesis in a mouse model of BRCA1 mutation. Mice with conditional loss of full-length BRCA1 targeted to mammary epithelial cells in association with germline TP53 insufficiency were treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.